The panelists believe healthcare reform transparency has caused a significant reduction in pricing variability, and this has prompted many providers to try to renegotiate rates. Such transparency is also pushing providers to make their pricing information more freely accessible on-line, yet there is some concern that antitrust laws are being used to squash this nascent movement.
Healthcare pricing variability is decreasing tremendously, according to Francois de Brantes, MS, MBA, executive director, Health Care Incentives Improvement Institute, Newtown, Connecticut. Mr. de Brantes describes a report from the state of New Hampshire, the first state to regulate pricing transparency. The report indicates “There has been no effect in prices going up as a result of the transparency.”
This transparency and increased availability of pricing information is causing even the most expensive providers to try to find ways to renegotiate rates to keep their members. Blue Cross and Blue Shield of North Carolina has what Mr de Brantes considers “the most aggressive and well-done transparency tool on pricing.” In fact, “you don’t have to be a plan member… that information is freely accessible on the Web, and they show full episode costs for a number of things [and] the comparisons between the hospitals.”
Arthur Vercillo, MD, FACS, a surgeon and regional president of Excellus Blue Cross Blue Shield, acknowledges that higher-paid providers are worried about the current move toward transparency, “and that’s a good thing.” Dr Vercillo believes products are now being developed with pricing transparency in mind. He explains that nobody wants to be the one charging too little, nor the one charging too much.
Mr de Brantes believes there is no legitimacy to antitrust concerns related to price transparency. “All the arguments that have been put forth are bogus,” he insists, “because if they truly did violate a federal statute . . . or they violated consumer rights, the lawsuits would have gone up to the Supreme Court by now, and they haven’t.” Mr de Brantes adds, “There’s absolutely no legal standing for these arguments.” Dr Vercillo acknowledges the antitrust issue, but believes the benefits of transparency outweigh his concerns, and he is willing to “take the risk of the leverage that could be exerted because the benefit is that big, that important.”
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Mental Health Diagnoses, Care Challenges Rise Among US Youth, Report Finds
April 26th 2024While behavioral health care utilization has been rising, the treatment landscape has been worsening. New findings show that 20% of youths did not receive any form of treatment within 3 months of their initial behavioral health diagnosis.
Read More